HK1093736A1 - Processes and intermediates for the preparation of purine derivatives useful in the treatment of (inter alia) cancer, asthma and diarrhea - Google Patents

Processes and intermediates for the preparation of purine derivatives useful in the treatment of (inter alia) cancer, asthma and diarrhea

Info

Publication number
HK1093736A1
HK1093736A1 HK07100507.9A HK07100507A HK1093736A1 HK 1093736 A1 HK1093736 A1 HK 1093736A1 HK 07100507 A HK07100507 A HK 07100507A HK 1093736 A1 HK1093736 A1 HK 1093736A1
Authority
HK
Hong Kong
Prior art keywords
diarrhea
asthma
intermediates
cancer
processes
Prior art date
Application number
HK07100507.9A
Other languages
English (en)
Inventor
Elfatih Elzein
Rao Kalla
Tim Marquart
Jeff Zablocki
Xiaofen Li
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of HK1093736A1 publication Critical patent/HK1093736A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
HK07100507.9A 2003-11-21 2007-01-15 Processes and intermediates for the preparation of purine derivatives useful in the treatment of (inter alia) cancer, asthma and diarrhea HK1093736A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/719,102 US7125993B2 (en) 2001-11-09 2003-11-21 A2B adenosine receptor antagonists
PCT/US2004/038136 WO2005051951A1 (en) 2003-11-21 2004-11-15 A2b adenosine receptor antagonists

Publications (1)

Publication Number Publication Date
HK1093736A1 true HK1093736A1 (en) 2007-03-09

Family

ID=34633233

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07100507.9A HK1093736A1 (en) 2003-11-21 2007-01-15 Processes and intermediates for the preparation of purine derivatives useful in the treatment of (inter alia) cancer, asthma and diarrhea

Country Status (16)

Country Link
US (3) US7125993B2 (es)
EP (1) EP1685132B1 (es)
JP (1) JP4769728B2 (es)
KR (1) KR101140186B1 (es)
CN (1) CN100415748C (es)
AU (1) AU2004292529B2 (es)
CA (1) CA2546733C (es)
ES (1) ES2391178T3 (es)
HK (1) HK1093736A1 (es)
IL (1) IL175759A0 (es)
MX (1) MXPA06005637A (es)
NZ (1) NZ547357A (es)
RU (1) RU2374247C2 (es)
TW (1) TWI365879B (es)
WO (1) WO2005051951A1 (es)
ZA (1) ZA200604046B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
AU2001238665A1 (en) * 2000-02-23 2001-09-03 Cv Therapeutics, Inc. Method of identifying partial agonists of the a2a receptor
US20080318983A1 (en) * 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
CA2443023A1 (en) * 2002-02-01 2003-08-07 King Pharmaceuticals Research And Development, Inc. 8-heteroaryl xanthine adenosine a2b receptor antagonists
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
AU2003259264A1 (en) * 2002-07-29 2004-02-16 Cv Therapeutics, Inc. Myocardial perfusion imaging using a2a receptor agonists
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
NZ589657A (en) 2004-10-15 2012-06-29 Gilead Palo Alto Inc Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
CN101076343A (zh) 2004-10-20 2007-11-21 Cv医药有限公司 A2a腺苷受体激动剂的应用
EP2301937A1 (en) * 2005-06-16 2011-03-30 Cv Therapeutics, Inc. Prodrugs of A2b adenosine receptor antagonists
ES2270715B1 (es) * 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
ES2274712B1 (es) * 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
EP2581381A3 (en) 2006-02-03 2013-10-30 Gilead Sciences, Inc. Process for preparing an A2A-adenosine receptor agonist and its polymorphs
US7795268B2 (en) * 2006-03-17 2010-09-14 Gilead Palo Alto, Inc. Method of treating hepatic disease using A2B adenosine receptor antagonists
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
WO2008028140A1 (en) * 2006-09-01 2008-03-06 Cv Therapeutics, Inc. Methods and compositions for increasing patient tolerability during myocardial imaging methods
JP2011502101A (ja) * 2006-09-29 2011-01-20 ギリアード・パロ・アルト・インコーポレイテッド 肺疾患の病歴を有する患者における心筋画像化法
ES2303776B1 (es) * 2006-12-29 2009-08-07 Laboratorios Almirall S.A. Derivados de 5-fenil-6-piridin-4-il-1,3-dihidro-2h-imidazo(4,5-b)piridin-2-ona utiles como antagonistas del receptor de adenosina a2b.
CA2673653A1 (en) * 2007-01-03 2008-07-17 Cv Therapeutics, Inc. Myocardial perfusion imaging
US20110118276A1 (en) * 2008-07-16 2011-05-19 Edward Leung Methods of treating atherosclerosis
WO2010037122A1 (en) * 2008-09-29 2010-04-01 Gilead Palo Alto, Inc. Combinations of a rate control agent and an a-2-alpha receptor antagonist for use in multidetector computed tomography methods
CN103237548A (zh) 2010-06-30 2013-08-07 吉利德科学股份有限公司 A2b腺苷受体拮抗剂用于治疗肺高血压的应用
CA3093234A1 (en) 2018-03-05 2019-09-12 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof
MX2021008094A (es) 2019-01-11 2021-09-21 Omeros Corp Metodos y composiciones para el tratamiento del cancer.

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452788A (en) 1982-04-21 1984-06-05 Warner-Lambert Company Substituted 8-phenylxanthines
US4539707A (en) * 1982-06-01 1985-09-03 Aerotron, Inc. Compressed single side band communications system and method
US4593095A (en) 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US4558051A (en) 1983-10-11 1985-12-10 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
GB8510758D0 (en) 1985-04-27 1985-06-05 Wellcome Found Compounds
DE3843117A1 (de) 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
IT1229195B (it) 1989-03-10 1991-07-25 Poli Ind Chimica Spa Derivati xantinici ad attivita' broncodilatatrice e loro applicazioni terapeutiche.
DE4019892A1 (de) 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
WO1995011681A1 (en) 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
DE19535504A1 (de) 1995-09-25 1997-03-27 Bayer Ag Substituierte Xanthine
GB9703044D0 (en) 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
US6117878A (en) 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
EP0956855B1 (en) 1998-04-24 2003-03-12 K.U. Leuven Research & Development Immunosuppressive effects of 8 substituted xanthine derivatives
US6060481A (en) 1998-05-28 2000-05-09 The Penn State Research Foundation Method for improving insulin sensitivity using an adenosine receptor antagonist
WO1999062553A1 (fr) 1998-06-01 1999-12-09 Fujisawa Pharmaceutical Co., Ltd. Medicaments contre la sterilite masculine
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
US6545002B1 (en) 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
CN100467469C (zh) * 2001-11-09 2009-03-11 Cv医药有限公司 A2b腺苷受体拮抗剂
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists

Also Published As

Publication number Publication date
IL175759A0 (en) 2006-09-05
CA2546733A1 (en) 2005-06-09
JP2007512335A (ja) 2007-05-17
US20090137802A1 (en) 2009-05-28
RU2374247C2 (ru) 2009-11-27
TWI365879B (en) 2012-06-11
EP1685132B1 (en) 2012-08-29
KR20060100434A (ko) 2006-09-20
ES2391178T3 (es) 2012-11-22
RU2006117349A (ru) 2007-11-27
MXPA06005637A (es) 2006-08-17
AU2004292529B2 (en) 2011-04-14
TW200530237A (en) 2005-09-16
EP1685132A1 (en) 2006-08-02
WO2005051951A1 (en) 2005-06-09
AU2004292529A1 (en) 2005-06-09
US7125993B2 (en) 2006-10-24
KR101140186B1 (ko) 2012-05-23
CN100415748C (zh) 2008-09-03
US20040176399A1 (en) 2004-09-09
US20060281921A1 (en) 2006-12-14
NZ547357A (en) 2009-08-28
CA2546733C (en) 2015-03-17
JP4769728B2 (ja) 2011-09-07
US7521554B2 (en) 2009-04-21
CN1882588A (zh) 2006-12-20
ZA200604046B (en) 2007-11-28

Similar Documents

Publication Publication Date Title
HK1093736A1 (en) Processes and intermediates for the preparation of purine derivatives useful in the treatment of (inter alia) cancer, asthma and diarrhea
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
HK1099274A1 (en) Process for the preparation of 1,1,1,3,3-pentafluoropropane and 1,1,1,2,3- pentafluoropropane
EP1582131A4 (en) ROTATING CLEANING BODY AND MANUFACTURING METHOD FOR CLEANING BODY AND ROTATING CLEANING BODY
HK1098737A1 (en) Process for the preparation of 1,1,1,3,3-pentafluoro-2-chloropropene and 1,1,1,3,3,3-hexafluoro-2-chloropropane
HRP20050328A2 (en) Process for the preparation of (s,s)-cis-2-benzhyd
PL377227A1 (pl) Postawione pochodne heksahydropirazyno [1,2-a] pirymidyno-4,7-dionu, sposób ich wytwarzania i ich zastosowanie jako środków leczniczych
EP1576033A4 (en) PROCESS FOR PRODUCING POLYSILOXANES AND USE THEREOF
PT1583542E (pt) Composições e métodos para terapia de combinação antiviral
HK1085489A1 (en) Chitosan-containing polyaccharide, process for producing the same and use thereof
IL174512A0 (en) Pyrazolo and imidazo-pyrimidine derivatives
HUP0500851A2 (en) Process for the preparation of rosuvastatin
IL178261A0 (en) Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
HK1075844A1 (en) Formulation and methods for the treatment of thrombocythemia
AU2003280298A1 (en) Methods for the biological treatment of gas
EP1702214A4 (en) METHOD FOR THE TREATMENT OF ASTHMA
IL214387A (en) History of tryptamine, method for their preparation and use for the preparation of pharmaceuticals and for the preparation of tryptamine
AU2003212634A8 (en) Compounds useful in the treatment of cancer
AU2003271185A1 (en) Imidazopyridine derivative, process for producing the same, and use
EP1551388A4 (en) COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, COMPOSITIONS AND METHODS COMPRISING THE SAME
EP1670894A4 (en) COMPOSITIONS COMPRISING VARIOUS TYPES OF TRANSFER FACTOR, METHODS FOR PREPARING COMPOSITIONS, AND METHODS OF TREATMENT USING THE COMPOSITIONS
EG23973A (en) Process for the preparation of urea ganules
AU2003223538A1 (en) Methods for the treatment of cancer
HK1098131A1 (en) Bengamide derivatives, method for the production thereof and use thereof for the treatment of cancer
EP1491098A4 (en) METHOD FOR PRODUCING MULTIPURPOSE BASE SPICES AND THEIR USE

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20191112